
Analysis of PADA-1 Trial Highlights Kinetics and Determinants of ESR1 Mutations in HR+/HER2– Metastatic Breast Cancer
An analysis from the phase 3 PADA-1 trial (NCT03079011) examining the kinetics and determinants of ESR1 mutations detected in the blood of patients with hormone receptor–positive, HER2-negative metastatic breast cancer showed that the incidence of these …